NPTH.V - Biomed/telehealth stock trading below 1x revenues
NPTH is significantly undervalued compared to peers:
- 33M mkt cap with 50M revenue in 2019
- < 1 EV/sales vs 18.24x industry avg
- Recent 12M financing at .90
- Insider options at .87 + open market buys
- In major historical support zone
- 33M mkt cap with 50M revenue in 2019
- < 1 EV/sales vs 18.24x industry avg
- Recent 12M financing at .90
- Insider options at .87 + open market buys
- In major historical support zone
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.